An ultrasensitive method for the quantitation of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS

Bioanalysis

Volumn 6, Issue 1, 2014, Pages 33-42

  Chappell, Derek L ^a   Lee, Anita Y H ^a   Castro Perez, Jose ^a   Zhou, Haihong ^a   Roddy, Thomas P ^a   Lassman, Michael E ^a   Shankar, Sudha S ^a   Yates, Nathan A ^a,b   Wang, Weixun ^a   Laterza, Omar F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; UNCLASSIFIED DRUG;

ABSOLUTE RECOVERY; ACCURACY; ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; CONTROLLED STUDY; DILUTION LINEARITY; FOOD EFFECT; FOOD INTAKE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; IMMUNOPRECIPITATION EFFICIENCY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX EFFECT; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SPIKE RECOVERY; VALIDATION STUDY;

AMIDES; ANIMALS; ANTIBODIES; CALIBRATION; CHROMATOGRAPHY, LIQUID; EATING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IMMUNOASSAY; RABBITS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84890899602     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.13.280     Document Type: Article

References (21)

1. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. Nature 444(7121), 854-859 (2006).
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 132(6), 2131-2157 (2007).
3. Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 87(4), 1409-1439 (2007).
4. Mu J, Petrov A, Eiermann GJ et al. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. Eur. J. Pharmacol. 623(1-3), 148-154 (2009).
5. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm. Metab. Res. 36(11-12), 867-876 (2004).
6. Wolf R, Hoffmann T, Rosche F, Demuth HU. Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1), 91-99 (2004).
7. Zheng MY, Yang JH, Shan CY et al. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovasc. Diabetol. 12, 73 (2013).
8. Adenot M, de Menthiere CS, Kervran A, Grassy G. Peptide dynamic fingerprints: a tool for investigating the role of conformational flexibility for GLP-1 analogs affinity. J. Pept. Sci. 11(8), 463-471 (2005).
9. Heijboer AC, Frans A, Lomecky M, Blankenstein MA. Analysis of glucagon-like peptide 1; what to measure? Clin. Chim. Acta 412(13-14), 1191-1194 (2011).
10. Orskov C, Rabenhoj L, Wettergren A, H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43(4), 535-539 (1994).
11. Bak MJ. Specificity and sensitivity of commercially available methods for the measurement of human glucagon-like peptide-1 (GLP-1). Proceedings of American Diabetes Association 72nd Annual Meeting, PA, USA, 8-12 June 2012.
12. Ackermann BL. Understanding the role of immunoaffinity-based mass spectrometry methods for clinical applications. Clin. Chem. 58(12), 1620-1622 (2012).
13. Nicol GR, Han M, Kim J et al. Use of an immunoaffinity-mass spectrometry-based approach for the quantification of protein biomarkers from serum samples of lung cancer patients. Mol. Cell. Proteomics 7(10), 1974-1982 (2008).
14. Whiteaker JR, Paulovich AG. Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification. Clin. Lab. Med. 31(3), 385-396 (2011).
15. Zhou H, Castro-Perez J, Lassman ME et al. Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 27(12), 1294-1302 (2013).
16. Castro-Perez J. Evaluation of a novel microfluidic device for robust and ultrasensitive quantitative analysis of biomarkers and bio-therapeutics by LC-MS/MS. Presented at: 61st ASMS Conference on Mass Spectrometry and Allied Topics. Minneapolis, MN, USA,9-13 June 2013.
17. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 347(1-2), 3-11 (2009).
18. Wolf R, Hoffmann T, Rosche F, Demuth HU. Simultaneous determination of incretin hormones and their truncated forms from human plasma by immunoprecipitation and liquid chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 803(1), 91-99 (2004).
19. Herman GA, Stevens C, Van Dyck K et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin. Pharmacol. Ther. 78(6), 675-688 (2005).
20. Chappell DL, McAvoy T, Weiss B, Weiner R, Laterza OF. Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC-MS/MS. Bioanalysis 4(23), 2843-2850 (2012).
21. Lund H, Snilsberg AH, Halvorsen TG, Hemmersbach P, Reubsaet L. Comparison of newly developed immuno-MS method with existing DELFIA((R)) immunoassay for human chorionic gonadotropin determination in doping analysis. Bioanalysis 5(5), 623-630 (2013).